Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs, Consumer Health products and Original drugs. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide.
As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs.
We focus on three core activities:
• Selected and Advanced Generics
• Consumer Health products
• Original drugs
Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe.
At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.
As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs.
We focus on three core activities:
• Selected and Advanced Generics
• Consumer Health products
• Original drugs
Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe.
At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.
Location: Switzerland, Geneva, Plan-les-Ouates
Employees: 51-200
Phone: +41 22 799 19 19
Founded date: 1990
Investors 2
| Date | Name | Website |
| 15.07.2021 | ArchiMed | archimed-g... |
| - | ArchiMed | archimed.g... |
Mentions in press and media 2
| Date | Title | Description |
| 24.06.2021 | Andreessen Horowitz gears up for more mega crypto bets | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content The gender pay gap and your investment strategies From Refinitiv Venture capitalists... |
| 24.06.2021 | Andreessen Horowitz gears up for more mega crypto bets | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Change your marketer experience and unleash growth for your business From Optimizely... |